Kornimate/medical-research-clean huggingface dataset:
driving ability among people with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to assess the effect of mci on driving ability by using on road driving test. the relationship between their driving outcome and their cognitive decline will be examined.

each subject will be evaluated by test battery which is accepted to driving assessment and include: the montreal cognitive assessment, clock drawing task, color trail test, motor free visual perception, visual spatial search task , awareness questionnaire and on road driving test. the difference between outcome measures of the on road test between the patient group and the control group will be tested. the correlation between outcome measures of the on road test and the cognitive tests will be examined.

Eligibility criteria:
inclusion criteria: * diagnosis of mild cognitive impairment(given by a neurologist), valid driver's license and driving experience of at least a year. exclusion criteria: * people diagnosed with other neurological damage such as: dementia, cva and head injury, people with sensory or motor impairment

Keywords: mild cognitive impairment automobile driving cognitive aspects
post-operative pain after shoulder surgery

Conditions: Pain, Shoulder

Summary: a prospective observational study conducted at the american university of beirut medical center that targets patients undergoing shoulder surgeries. it is conducted to to prospectively collect patient, surgery and anesthesia-related variables and perform correlation studies with postoperative pain severity, patients' satisfaction and analgesic consumption following shoulder surgery. in addition, identifying predictors for postoperative pain will contribute to adjust pain management protocols as per surgical and patients' factors.


Eligibility criteria:
inclusion criteria: * all adult patients \> 18 years old admitted to the american university of beirut - medical center for any shoulder surgery exclusion criteria: * patients suffering of opioids addiction (or previous history of addiction) or drug abuse.
manual therapy in chronic shoulder pain treatment

Conditions: Shoulder Pain

Summary: background: passive oscillatory mobilizations are often employed by physiotherapists to reduce shoulder pain and increase function. however, there is little data about the neurophysiological effects of these mobilizations. objectives: to investigate the initial effects of an anteroposterior (ap) shoulder joint mobilization on measures of pain and function in overhead athletes with chronic shoulder pain.

design: double-blind, controlled, within-subjects repeated-measures design method: thirty-one overhead athletes with chronic shoulder pain participated. the effects of a 9-min, ap mobilization of the glenohumeral joint were compared with manual contact and no-contact interventions. pressure pain threshold (ppt), range of movement (rom), muscle strength, self-reported pain, and disability were measured immediately before and after each intervention.

Eligibility criteria:
inclusion criteria: * history of chronic shoulder pain lasting ≥3 months. * play overhead sport regularly. exclusion criteria: * had a non-musculoskeletal origin of shoulder pain. * previous surgery to the shoulder complex. * frozen shoulder. * any co-existing inflammatory, infectious or neurological condition. * the patient from physiotherapy treatment. * any evidence of pain referred from the cervical spine to the shoulder
structured trauma quality improvement meetings at four trauma centres in india

Conditions: Major Trauma; Injuries Major

Summary: a prospective before-and-after study to evaluate the effect of implementing a trauma quality improvement protocol on the process of trauma quality improvement meetings and major trauma patient outcomes at four trauma centres in india.

this project will be conducted as a prospective before-and-after study at four major trauma centres in india, with the intervention occurring between pre- and post-intervention phases. included in the study will be all patients presenting to any of the four trauma hospitals with a potentially life-threatening or limb-threatening injury. the intervention will be the introduction of a structured trauma quality improvement meeting (tqim), using a checklist and training program. the primary outcome will be compliance with the tqim checklist, measured as the proportion of discussed cases (trauma deaths) for which problems with care, preventability and corrective actions were discussed and / or agreed. the secondary outcomes will include in-hospital risk-adjusted mortality, hospital length of stay and time to emergency surgery. data collection will occur at all meetings at the four trauma hospitals at which trauma deaths are discussed. data will also be collected in a dedicated trauma registry.

Eligibility criteria:
inclusion criteria: * all patients presenting to any of the four study sites with a potentially life-threatening or limb-threatening injury. specifically, all presenting injured patients triaged as "red" or "yellow" according to the australia-india trauma systems collaboration (aitsc) trauma triage protocol, will meet the screening criteria for data collection. retrospective inclusion in the registry will be continued for all screened patients presenting to any of the included hospitals with injury (including near-drowning) as the primary diagnosis and with at least one of the following criteria: * admission to hospital * death after triage but before admission exclusion criteria: * the exclusion criteria for the aitsc trauma registry are: * death at scene * alive at triage but not admitted to hospital * isolated poisoning * isolated burns * single digit finger or toe amputations

Keywords: quality improvement injury injuries
a controlled trial comparing the efficacy of aerosolized pentamidine and parenteral / oral trimethoprim - sulfamethoxazole in the treatment of pneumocystis carinii pneumonia in aids

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: this is a randomized double-blinded controlled study comparing aerosolized pentamidine with trimethoprim plus sulfamethoxazole (tmp / purposex). the latter drug will be administered intravenously for at least 5 days, then changed to oral administration if warranted by the patient's clinical condition.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * zidovudine as long as such therapy is suspended prior to randomization and not reinstituted until therapy for the acute episode is completed. pneumocystis carinii pneumonia (pcp) in an adult who is hiv positive by elisa, hiv culture, or p24 antigenemia, or is a member of a risk group for hiv infection (homosexual or bisexual men, intravenous drug abusers, recipients of hiv infected blood products, and the sexual partners of the foregoing groups). * the patient must have a resting alveolar - arterial oxygen (a-a) do2 less than 30 mmhg on room air at all actg sites, except san francisco general hospital. other sites will enter patients up to a resting (a-a) do2 = or \< 55 mmhg on room air. prior medication: allowed: * zidovudine as long as such therapy is suspended prior to randomization and not reinstituted until therapy for the acute episode is completed. exclusion criteria co-existing condition: patients with the following are excluded: * dyspnea. * cough. * bronchospasm. * history of a major adverse reaction to pentamidine or sulfonamide containing preparations. patients with the following will be excluded: * inability to cooperate with aerosol administration because of dyspnea, cough, bronchospasm, or other reasons. * history of a major adverse reaction to pentamidine or sulfonamide containing preparations. * in the opinion of the investigator, the patient would not complete therapy or follow-up for social reasons. prior medication: excluded within 14 days of study entry: * systemic steroids above adrenal replacement doses. * excluded within 6 weeks of study entry: * other antiprotozoal regimen for this episode such as trimethoprim / sulfamethoxazole (tmp / purposex). * pyrimethamine. * fansidar. * pentamidine. * eflornithine (dfmo). * dapsone, whether therapeutic or prophylactic, or any of these agents.

Keywords: trimethoprim-sulfamethoxazole combination aids-related opportunistic infections pneumonia, pneumocystis carinii pentamidine injections, intravenous administration, oral aerosols acquired immunodeficiency syndrome
an extension study to further evaluate the safety, tolerability of gbt440 in patients with sickle cell disease who participated in the study gbt440-001

Conditions: Sickle Cell Disease

Summary: this is an open label, single arm study which enrolled 5 subjects with scd who previously participated in the gbt440-001 study (nct02285088).

this is an open label, single arm study which enrolled 5 subjects with scd who previously participated in the gbt440-001 study (nct02285088). dosing of study drug was 2 to 6 months, depending on subject's dose assignment in the last administration of study drug in gbt440-001 (nct02285088). the primary objective of the study was to evaluate the safety and tolerability of up to a total of 6 months dosing of subjects with scd who participated in the gbt440-001 study (nct02285088).

Eligibility criteria:
inclusion criteria: 1. male or female subjects with scd aged 18 to 60 years inclusive and \>50 kg who have participated in the gbt440-001 study. 2. subjects, who if female and of child bearing potential, agree to continue to use highly effective methods of contraception prior to enrollment in this study and for 3 months after the last dose of study drug. 3. subjects, who if male are willing to continue to use barrier methods of contraception, prior to enrollment in this study to 3 months after the last dose of study drug. exclusion criteria: 1. subjects requiring chronic transfusion therapy. 2. subjects receiving a blood transfusion within 30 days of enrollment in this study. 3. female subjects who are pregnant, trying to become pregnant or lactating. 4. subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders, or additional risk factors for torsades de pointe (e.g., heart failure, hypokalemia, personal or family history of long qtc interval). 5. subjects who have a significant infection or known inflammatory process on admission to this study. 6. subjects who have acute gastrointestinal symptoms at the time of admission (e.g. nausea, vomiting, diarrhoea, heartburn).
an eight-week study to evaluate the efficacy and safety of sr58611a in elderly patients with depression

Conditions: Depressive Disorder

Summary: the purpose of the study is to evaluate the efficacy and safety of sr58611a in elderly patients with depression.the primary objective is to evaluate the efficacy of a 700 mg dose of sr58611a compared to placebo in elderly patients with depression. the secondary objectives are to evaluate the safety of sr58611a and to evaluate the efficacy of sr58611a on disability and quality of life in elderly patients with depression.


Eligibility criteria:
inclusion criteria: * outpatients or inpatients * major depressive disorder (mdd) with a recurrent major depressive episode (mde) according to dsm iv-tr criteria. * madrs score equal of above 22. exclusion criteria: * patients with a current significant risk of suicide in the investigator's clinical judgment. * the duration of the current depressive episode is greater than 2 years. * patients whose current depressive episode is secondary to a general medical condition * patients with a lifetime history according to mini at screening of:bipolar disorder, psychotic disorder, antisocial personality disorder. * patients with a current history according to mini at screening of anxiety disorders, alcohol dependence or abuse or substance dependence or abuse * patients with severe or unstable concomitant medical conditions. * history of seizures other than a single childhood febrile seizure. * patients with abnormal thyroid functioning. * patients with clinically significant ecg findings at screening. * patients who have taken an investigational drug in the last 3 months prior to screening. * any subject who has previously participated in a sr58611a protocol. * patients with mini-mental state examination (mmse) score \< 25 at screening.

Keywords: depression antidepressive agents controlled clinical trial
comparative effects of propioceptive neuromascular facilitation and neural flossing in diabetic neuropathy

Conditions: Diabetic Peripheral Neuropathy

Summary: to compare the effects of propioceptive neuromascular facilitation and neural flossing on balance and gait in diabetic peripheral neuropathy.

in 2023,conducted systematic review to evaluate the effects of tai chi on postural control in people with pn. the meta-analysis found that tai chi therapy for people with pn resulted in a smaller sway area, in the double-leg stance with eyes closed test , than that observed in the control group, greater distance covered in the six-minute walking test and faster performance in the timed-up-and-go test, than the baseline. tai chi effectively enhanced dynamic postural control in people with pn. however, no better effects on postural control from tai chi than from other rehabilitation approaches were observed in this study. in 2023,compare the effects of functional strength training versus neurodynamic exercises on balance and gait of patients with diabetic peripheral neuropathy. both functional strength training exercises and neurodynamic exercises were found to improve the balance and gait in patients with diabetic peripheral neuropathy. however, the functional strength training showed more significantly improvement in balance and gait subsequently reducing fall and fall risk injury. as per researcher knowledge, there is no comprehensive study comparing the effects of proprioceptive neuromuscular facilitation (pnf) and neural flossing on balance and gait in individuals with diabetic neuropathy. while both methods have been studied independently, a direct head-to-head comparison is needed. understanding the advantages and limitations of each approach in the context of diabetic neuropathy could provide valuable insights for clinicians and researchers.

Eligibility criteria:
inclusion criteria: * clinically diagnosed with type i and ii diabetes * patients 45 to 65 years of age * the participants who scored \<3 as per the michigan neuropathy screening instrument (mnsi) were included in the study. * able to stand and walk without assistance exclusion criteria: * patients have other neurological or orthopedic impairments (such as stroke,cerebral palsy, poliomyelitis, rheumatoid arthritis, prosthesis, or moderate or severe osteoarthritis) * major vascular complications (venous or arterial ulcers). * severe retinopathy * severe nephropathy that causes edema or requires haemodialysis

Keywords: diabetic peripheral neuropathy michigan neuropathy screening instrument neural flossing propioceptive neuromascular facilitation
poised for parkinson's - an intervention to increase embodied agency in people with parkinson's disease and their carers

Conditions: Parkinson's Disease

Summary: the purpose of the study is to develop, deliver, and test an online alexander-based training program for people with parkinson's disease and their care partners.

six dyads, each consisting of a person with parkinson's disease and their care partner, will participate in a real-time online course called "poised for parkinson's." the course will meet twice per week via zoom for eighteen 105-minute sessions. outcome measures, including surveys, interviews, balance, and motor performance, will be assessed the week before classes begin and the week after classes end.

Eligibility criteria:
inclusion criteria: * dyad including care partner and person with parkinson's disease * hoehn \& yahr stage 2 (estimated) * vision and hearing (corrected to) normal * able to use computer, internet, and zoom * ambulatory without assistive devices * reside in idaho exclusion criteria: * dementia (screen with moca) * severe musculoskeletal pain (screen in interview)

Keywords: alexander technique posture mindfulness embodiment caregivers movement interventions complementary integrative medicine non-pharmacological interventions quality of life
cognitive screening and cognitive training in seniors

Conditions: Mild Cognitive Impairment

Summary: this study will provide cognitive screenings for seniors age 50 and older. it will also investigate the benefits of two different cognitive training programs for seniors who have lower baseline performance on memory and/or gist reasoning tests.

this study consists of two parts which includes cognitive screening and cognitive training. participants will initially participate in the cognitive screening portion of the study. if qualified, participants will participate in the cognitive training portion of this study which includes additional cognitive communication, neuropsychological testing, and eeg.

Eligibility criteria:
inclusion criteria: * cognitive complaints in the absence of dementia * participate in tasks involving motor abilities such as use of at least one arm and hand * read, speak, and comprehend english * at least 50 years of age * comprehend simple instructions, perform tasks, and take part in intervention exclusion criteria: * not proficient in reading,comprehending, and speaking english * history of learning disability, stroke, cognitive impairment, major psychiatric illness, alcoholism, or substance abuse
efficacy/safety study to explore a new topical formulation in atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: the study shall explore whether treatment of atopic dermatitis is equally effective with phoenix medical device as compared to standard therapy (hydrocortisone cream).


Eligibility criteria:
inclusion criteria: * male or female caucasians aged between 18 and 60 years * patients with mild atopic dermatitis (ad) presenting a scoring ad (scorad) rating below 50 * skin type i - iv according to fitzpatrick * acute ad symptoms on each assessment areas (local scorad ≥ 3 and \<= 12) at baseline * acute symptom of pruritus at baseline exclusion criteria: * any other skin disease at the test area that would interfere with the clinical assessment in the opinion of the investigator * moles, tattoos, strong pigmentation, or scars at the test area that would interfere with the clinical assessment * regular intake of antiphlogistic drugs (for example nonsteroidal anti-inflammatory drugs \[nsaids\]) * any condition or treatment which might influence the trial (e.g. any treatment with topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as well as during the trial (exception: topical treatment of ad lesions other than the test areas (for example, face) with low potency steroids restricted to small areas) * uv-therapy or the use of solarium within 30 days before screening as well as during the trial * any alternative treatment of ad (e.g. acupuncture, kinesiology, and homoeopathy) within 30 days before screening as well as during the trial

Keywords: phoenix hydrocortison mild atopic dermatitis efficacy safety
study of inactivity on metabolism of elderly muscles

Conditions: Sarcopenia

Summary: skeletal muscle mass declines with inactivity (casting is a good example) and increases with activity (such as weightlifting). whether muscle mass increases or decreases, is determined by whether more new proteins within muscle are made than are broken down. the investigators know that feeding protein increases the synthesis of new proteins but that the response of older muscles to protein feeding is blunted compared with the young. this resistance of the elderly to muscle building stimuli may be the primary reason that muscle mass is lost in aging. the investigators also know that periods of muscle disuse such as casting result in a person's muscle shrinking due, the investigators believe, to a lower rate of synthesis of new muscle proteins. age-related muscle loss begins around 50 years old and proceeds at approximately 1% for every year after. elderly persons would likely fare well with advancing age if their muscle loss were simply linear; however, a rate of muscle loss of 1% annually is a 'population view' and does not represent what occurs during short periods of muscle disuse (i.e. during hospitalization or illness), which occur with increasing frequency in elderly persons. during periods of disuse, the resistance of elderly muscles to protein nutrition may be worsened. the investigators will measure how quickly new proteins are made at rest and after protein feeding in elderly men, before and after a 14 day period of reduced activity brought on by having people reduce their daily step count.


Eligibility criteria:
inclusion criteria: * male or female * aged 60 to 80 years old * non-smoker generally healthy and can tolerate the resistance exercise and protein drink exclusion criteria: * allergies to whey protein * health problems such as: heart disease, rheumatoid arthritis of the knee joint, diabetes, poor lung function, uncontrolled hypertension, or any health conditions that might put participants at risks for this study * failed an exercise stress test * taking metformin and/or other medications for the control of blood glucose even though one might not be classified as diabetic * taking prescribed blood thinners such as warfarin and heparin but excluding aspirin * taking medications for lung and kidney conditions but excluding medication for asthma that is under control

Keywords: sarcopenia muscle reduced activity insulin sensitivity protein step reduction muscle protein synthesis whey protein leg strength whole body protein